These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18751872)

  • 1. Increased macrophage colony-stimulating factor levels in patients with Graves' disease.
    Morishita E; Sekiya A; Hayashi T; Kadohira Y; Maekawa M; Yamazaki M; Asakura H; Nakao S; Ohtake S
    Int J Hematol; 2008 Oct; 88(3):272-277. PubMed ID: 18751872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum granulocyte colony-stimulating factor levels in patients with Graves' disease.
    Iitaka M; Noh JY; Kitahama S; Fukasawa N; Miura S; Kawakami Y; Kawasaki S; Yamanaka K; Ishii J; Katayama S; Ito K
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):275-80. PubMed ID: 9578815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of thyroid states and serum thrombomodulin (TM) levels in patients with Graves' disease: TM, a possible new marker of the peripheral activity of thyroid hormones.
    Morikawa Y; Morikawa A; Makino I
    J Clin Endocrinol Metab; 1993 Mar; 76(3):609-14. PubMed ID: 7680353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased plasma levels of free tissue factor pathway inhibitor in patients with Graves' disease.
    Morishita E; Hashimoto T; Asakura H; Saito M; Yamazaki M; Aoshima K; Yoshida T; Kato H; Matsuda T
    Thromb Haemost; 1998 May; 79(5):919-23. PubMed ID: 9609221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship among thyrotropin (TSH), thyroid stimulating immunoglobulins, and results of triiodothyronine (T3) suppression test in patients with Graves' disease.
    Horimoto M; Nishikawa M; Uno C; Yoshikawa N; Taniguchi N; Inada M
    Endocrinol Jpn; 1988 Dec; 35(6):841-8. PubMed ID: 2471633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Change in serum G-CSF levels in patients with Graves' disease by treatment with methimazole].
    Hara H; Ban Y; Sato R; Ishikawa N; Yoshimura H; Hisaoka T; Ito K
    Nihon Naibunpi Gakkai Zasshi; 1992 Oct; 68(10):1121-9. PubMed ID: 1281122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking.
    Salvi M; Pedrazzoni M; Girasole G; Giuliani N; Minelli R; Wall JR; Roti E
    Eur J Endocrinol; 2000 Aug; 143(2):197-202. PubMed ID: 10913938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased serum neopterin levels in patients with Graves' disease.
    Wagner R; Hayatghebi S; Rosenkranz M; Reinwein D
    Exp Clin Endocrinol; 1993; 101(4):249-54. PubMed ID: 8307114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fluctuations in the titers of anti-thyroid hormone and anti-thyroglobulin antibodies in 4 cases of Graves' disease during long-term treatment period].
    Komaki T; Sakata S; Nakamura S; Matsuda M; Kojima N; Takuno H; Miura K
    Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):627-39. PubMed ID: 2583311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
    Chen JJ; Ladenson PW
    J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
    J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum thyrotropin in Graves' disease: a more reliable index of circulating thyroid-stimulating immunoglobulin level than thyroid function?
    Kabadi UM; Premachandra BN
    Endocr Pract; 2007 Oct; 13(6):615-9. PubMed ID: 17954417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistently increased gastrin and decreased pepsinogen concentrations in serum from some patients with Graves' disease of triiodothyronine-predominant type and common type.
    Fukao A; Takamatsu J; Shimamoto C; Kuma K; Ohsawa N
    Thyroid; 1998 Mar; 8(3):259-63. PubMed ID: 9545113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in serum glycosaminoglycan profiles in Graves' patients.
    Komosińska-Vassev K; Winsz-Szczotka K; Olczyk K; Koźma EM
    Clin Chem Lab Med; 2006; 44(5):582-8. PubMed ID: 16681428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cytokines in thyrotoxicosis.
    Siddiqi A; Monson JP; Wood DF; Besser GM; Burrin JM
    J Clin Endocrinol Metab; 1999 Feb; 84(2):435-9. PubMed ID: 10022397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating microRNA-1a is a biomarker of Graves' disease patients with atrial fibrillation.
    Wang F; Zhang SJ; Yao X; Tian DM; Zhang KQ; She DM; Guo FF; Zhai QW; Ying H; Xue Y
    Endocrine; 2017 Jul; 57(1):125-137. PubMed ID: 28547036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid hormone modulates insulin-like growth factor-I(IGF-I) and IGF-binding protein-3, without mediation by growth hormone, in patients with autoimmune thyroid diseases.
    Inukai T; Takanashi K; Takebayashi K; Fujiwara Y; Tayama K; Takemura Y
    Horm Metab Res; 1999 Oct; 31(10):576-9. PubMed ID: 10596968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.